Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Clinical trial NCT06435260 · RECRUITING

Trial details

NCT number: NCT06435260
Sponsor: Hebei Medical University Fourth Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Cancer

Start date: 2024-08-01
Primary completion: 2025-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.